10x Genomics today announced a multi-year collaboration with Dana-Farber Cancer Institute to perform single-cell and spatial profiling on tumor samples from more than 300 patients across major solid cancer types, including breast, lung and colorectal malignancies. Using its Chromium Flex single-cell assay and Xenium spatial platform, the company will generate high-resolution maps of cellular composition and tissue architecture to uncover biomarkers linked to response, resistance and progression under emerging therapies such as antibody-drug conjugates, radioligand treatments, bispecific antibodies and checkpoint inhibitors. By integrating these molecular profiles with clinical outcomes data, the teams aim to distinguish the biological signatures that separate responders from non-responders and to lay the groundwork for a standardized clinical reporting framework to guide oncologists in selecting precision treatments.

To support future diagnostic applications, 10x Genomics will establish a CLIA-certified laboratory in Pleasanton, California, equipped for analytical validation, clinical sample processing and regulated assay implementation. The new facility will enable 10x to transition research-grade workflows into assays suitable for clinical decision-making and will serve as the launchpad for the company’s next-generation diagnostic offerings. Management expects the lab build-out to be completed in the second half of 2026, allowing 10x to begin pilot diagnostic studies by early 2027 and to engage biopharma partners in co-developing assays that leverage its single-cell and spatial biology platforms for precision oncology.

This initiative represents 10x’s first foray into regulated clinical testing and underscores the company’s shift from purely research tools toward integrated diagnostic solutions. By combining its market-leading single-cell and spatial technologies with a CLIA-certified lab, 10x is positioning itself to capture a share of the precision oncology diagnostics market, forecast to exceed $10 billion by 2030. Investors should monitor initial pilot studies and regulatory milestones, as successful assay validations and early partnerships with biopharma could unlock new recurring revenue streams and bolster long-term margin expansion.